Boehringer Ingelheim R & D pushes to transcend disease boundaries

Family-owned pharmaceutical company Boehringer Ingelheim has presented its latest pipeline updates at a Research & Development press conference entitled 'Transcending Disease Boundaries', at its global headquarters in Ingelheim, Germany. The company's R&D strategy and current pipeline has the potential to deliver 15 new medicines for approval by 2025 (probability adjusted).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news